Research Summary

Analyzed using Evidence Intelligence™

Finerenone reduces heart and kidney event risk in CKD and T2D

Key finding

Crude event rates for the kidney composite outcome were lower with finerenone versus placebo under treatment (kidney: 1.09 vs. 1.71).

This study evaluated the effects of finerenone on heart and kidney events in patients with chronic kidney disease and type 2 diabetes, finding significant reductions in event rates compared to placebo.

Evidence strength

Moderate confidence

Study type

RCTs

Follow-up

Short-Term (≤3 mo)

High bias

Last updated July 6, 2026

Quick read

Study at a glance

The essential study design details in one scan.

Population

Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes

Intervention

Finerenone

Study type

RCTs

Follow-up

Short-Term (≤3 mo)

Primary outcome

Composite kidney outcome

Comparator

Placebo

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

Clinical relevance

These findings are clinically significant as they suggest that finerenone may offer a valuable treatment option for patients with chronic kidney disease and type 2 diabetes, potentially reducing the burden of heart and kidney-related complications. This could lead to improved patient management strategies and better health outcomes in this high-risk population.

Keep in mind

The study's findings may not be generalizable to all populations with diabetes. The long-term effects of finerenone after treatment discontinuation were not fully assessed. Adverse events were reported but not significantly different between groups.

Published in

Journal Reference

Publication details and source links for this paper.

Ajay KS, Stefan DA, Bertram P, et al. Finerenone Reduces Risk of Heart and Kidney Events in Patients with Chronic Kidney Disease and Type 2 Diabetes. American Journal of Nephrology. 2026. doi:10.1159/000549873

View DOI View on PubMed View on PMC

Save this study and add notes to your research library.

Main Effects

Finerenone reduced the composite kidney outcome event rate to 1.09 compared to 1.71 for placebo.

Finerenone reduced the composite cardiovascular outcome event rate to 2.98 compared to 3.78 for placebo.

The incidence of heart failure and myocardial infarction was lower with finerenone, but effects diminished after discontinuation.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Finerenone (nonsteroidal mineralocorticoid receptor antagonist) and Adverse events incidence, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization), Composite cardiovascular outcome, and 4 more.

This study contributes evidence to

Intervention

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

Outcome

Adverse events incidence

Evidence topic

Cardiovascular Risk

Primary intervention

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

Primary outcomes

Adverse events incidence
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Composite cardiovascular outcome

Evidence topics

Cardiovascular Risk

Primary intervention

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

Primary outcomes

Adverse events incidence Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)Composite cardiovascular outcome

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 63

Why it is useful

Contributes to 7 evidence relationships
Includes primary outcome data
Linked to 1 direct semantic evidence topic

Topic contributions

Evidence topic

Contributes evidence

Core evidence

Study findings

The primary outcomes reported in this study.

NoneNo Change

Adverse events incidence

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Adverse events incidence

Evidence profile

NoneNo ChangeSafety

Unlock full evidence details

StrongDecrease

Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence profile